Ovarian Cancer News and Research RSS Feed - Ovarian Cancer News and Research Twitter

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
IDMC recommends continuation of PM1183 Phase III trial in platinum-resistant ovarian cancer patients

IDMC recommends continuation of PM1183 Phase III trial in platinum-resistant ovarian cancer patients

PharmaMar announced today that the Independent Data Monitoring Committee has notified the Company of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian cancer patients should continue without any changes. [More]
MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. [More]
Increased breastfeeding could save over 800000 children’s lives annually

Increased breastfeeding could save over 800000 children’s lives annually

Just 1 in 5 children in high-income countries are breastfed to 12 months, whilst only 1 in 3 children in low and middle-income countries are exclusively breastfed for the first 6 months. [More]
Costs of lower cognitive ability linked with not breastfeeding amount to over $300 billion each year

Costs of lower cognitive ability linked with not breastfeeding amount to over $300 billion each year

When countries, rich or poor, support breastfeeding through meaningful investments and programs, it has an impact on their bottom line and the health of women and children. The Lancet Breastfeeding Series, released today, finds that globally, the costs of lower cognitive ability associated with not breastfeeding amount to more than $300 billion each year, a figure comparable to the entire global pharmaceutical market. [More]
Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center. [More]
AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX Technologies, Inc., a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer. [More]
ROCA Test now available in nine additional U.S. states for early detection of ovarian cancer

ROCA Test now available in nine additional U.S. states for early detection of ovarian cancer

Abcodia, a commercial stage company focused on the development of proprietary tests for the early detection of cancer, today announced expanded U.S. availability of the ROCA Test. [More]
Oestrogen supplements could reduce dementia risk in women

Oestrogen supplements could reduce dementia risk in women

Women who take oestrogen supplements from before or at the start of menopause and continue with them for a few years have better preserved brain structure, which may reduce the risk of dementia. [More]
Researchers identify biomarkers that may influence potential new drug design or alternative treatments of cancer

Researchers identify biomarkers that may influence potential new drug design or alternative treatments of cancer

Researchers have discovered gene-targets (biomarkers) that may enable alternative treatments or the potential design of new drugs that target metastasis-promoting tumor genes. [More]
Women who carry inherited fault in BRIP1 gene at higher risk of developing ovarian cancer

Women who carry inherited fault in BRIP1 gene at higher risk of developing ovarian cancer

Women who carry an inherited fault in the gene BRIP1 are over three times more likely to develop ovarian cancer than those without the fault, according to a study published in the Journal of the National Cancer Institute. [More]
New method could improve accurate diagnosis of ovarian cancer before surgery

New method could improve accurate diagnosis of ovarian cancer before surgery

In a landmark study, investigators from Europe propose a new and simple method to assess the risk of malignancy of women with an adnexal mass. The method identified between 89-99% of patients with ovarian cancer using the results of ultrasound examination, which can be obtained in referral and non-referral centers. [More]
Combination of PARP inhibitors and c-MET may benefit breast cancer patients

Combination of PARP inhibitors and c-MET may benefit breast cancer patients

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers. [More]
Auranofin drug could improve prognosis for ovarian cancer patients exhibiting BRCA1 deficiency

Auranofin drug could improve prognosis for ovarian cancer patients exhibiting BRCA1 deficiency

An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests. [More]
Promising novel approach to treat gynecologic tumors

Promising novel approach to treat gynecologic tumors

UCLA scientists have developed a promising novel method to treat gynecologic tumors. The approach focuses on a protein called p53, which is commonly mutated in women who have high-grade serous ovarian cancer, the deadliest form of reproductive cancer. In many women with the disease, the cancer is very advanced by the time it is diagnosed and is therefore difficult to treat. [More]
New study finds familial risk and heritability of cancer among twins

New study finds familial risk and heritability of cancer among twins

A large new study of twins has found that having a twin sibling diagnosed with cancer poses an excess risk for the other twin to develop any form of cancer. Among the 23 different types of cancer studied, an excess familial risk was seen for almost all of the cancers, including common cancers such as breast and prostate cancer, but also more rare cancers such as testicular cancer, head and neck cancer, melanoma, ovarian and stomach cancer. [More]
Northwest Biotherapeutics closes registered direct placement of $12.6M

Northwest Biotherapeutics closes registered direct placement of $12.6M

Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of its previously-announced registered direct placement with healthcare focused institutional investors, for gross proceeds of $12.6 million on the terms previously announced. [More]
Researchers reveal inherited genetic errors across 12 cancer types

Researchers reveal inherited genetic errors across 12 cancer types

Researchers long have known that some portion of the risk of developing cancer is hereditary and that inherited genetic errors are very important in some tumors but much less so in others. [More]
New study improves understanding of metal-based chemotherapy drugs

New study improves understanding of metal-based chemotherapy drugs

What is the mechanism of action of metal-based chemotherapy drugs (the most widely used for treating common cancers like testicular or ovarian cancer)? How can we improve their effect and reduce their toxicity? A new study combining experiments and theory has broadened our knowledge of the molecular mechanisms of these active drugs to help experimentalists devising increasingly effective drugs with fewer side effects. [More]
Ovarian cancer screening may help save lives

Ovarian cancer screening may help save lives

New results from the world's biggest ovarian cancer screening trial led by UCL suggest that screening based on an annual blood test may help reduce the number of women dying from the disease by around 20%. [More]

Clinical trial data indicate that screening reduces mortality from ovarian cancer

Screening appears to reduce mortality due to ovarian cancer, according to the results of The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial published in the Lancet yesterday. [More]
Advertisement
Advertisement